EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials

Antonio Cano iD, Rossella E Nappi, Nanette Santoro, Petra Stute, Martin Blogg, Marci L English, Antonia Morga, Ludmila Scrine, Emad Siddiqui, Faith D Ottery

BJOG: An International Journal of Obstetrics & Gynaecology · 2024-08 · 131 (9) · 1296-1305

DOI: 10.1111/1471-0528.17773 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, online erschienen am 06.02.2024. Verfasst von Antonio Cano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Obstetrics and Gynaecology, INCLIVA, University of Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Quality of Life, Hot Flashes, Menopause. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the effect of fezolinetant treatment on health‐related quality of life using pooled data from SKYLIGHT 1 and 2 studies.

Design

Prespecified pooled analysis.

Setting

USA, Canada, Europe; 2019–2021. Population 1022 women aged ≥40 to ≤65 years with moderate‐to‐severe vasomotor symptoms (VMS; minimum average seven hot flushes/day), seeking treatment for VMS.

Methods

Women were randomised to 12‐week double‐blind treatment with once‐daily placebo or fezolinetant 30 or 45 mg. Completers entered a 40‐week, active extension (those receiving fezolinetant continued that dose; those receiving placebo re‐randomised to fezolinetant received 30 or 45 mg). Main outcome measures Mean changes from baseline to weeks 4 and 12 on Menopause‐Specific Quality of Life (MENQoL) total and domain scores, Work Productivity and Activity Impairment questionnaire specific to VMS (WPAI‐VMS) domain scores, Patient Global Impression of Change in VMS (PGI‐C VMS); percentages achieving PGI‐C VMS of ‘much better’ (PGI‐C VMS responders). Mean reduction was estimated using mixed model repeated measures analysis of covariance.

Results

Fezolinetant 45 mg mean reduction over placebo in MENQoL total score was −0.57 (95% confidence interval [CI] −0.75 to −0.39) at week 4 and −0.47 (95% CI −0.66 to −0.28) at week 12. Reductions were similar for 30 mg. MENQoL domain scores were also reduced and WPAI‐VMS scores improved. Twice as many women receiving fezolinetant reported VMS were ‘much better’ than placebo based on PGI‐C VMS assessment.

Conclusions

Fezolinetant treatment was associated with improvement in overall QoL, measured by MENQoL, and work productivity, measured by WPAI‐VMS. A high proportion receiving fezolinetant felt VMS were ‘much better’ based on PGI‐C VMS responder analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeHot FlashesMenopauseHumansFemaleMiddle AgedDouble-Blind MethodAdultAgedTreatment Outcome

Stichwörter der Autor:innen

fezolinetanthealth‐related quality of lifeneurokinin 3 receptor antagonistpatient‐reported outcomesvasomotor symptoms

Autor:innen und Institutionen

  • Department of Paediatrics, Obstetrics and Gynaecology, INCLIVA, University of Valencia, Valencia, Spain.
  • Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy.
  • Research Centre for Reproductive Medicine and Gynaecological Endocrinology - Menopause Unit, Fondazione Policlinico IRCCS S. Matteo, Pavia, Italy.
  • University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Department of Obstetrics and Gynaecology, Inselspital, Bern, Switzerland.
  • Astellas Pharma Europe Ltd, Addlestone, UK.

ORCID-Profile: Antonio Cano

Förderung

  • Astellas Pharma Inc.

Zitieren

APA

Cano, A., Nappi, R. E., Santoro, N., Stute, P., Blogg, M., English, M. L., Morga, A., Scrine, L., Siddiqui, E., & Ottery, F. D. (2024). Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG: An International Journal of Obstetrics & Gynaecology, 131(9), 1296-1305. https://doi.org/10.1111/1471-0528.17773

Vancouver

Cano A, Nappi RE, Santoro N, Stute P, Blogg M, English ML, et al. Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG: An International Journal of Obstetrics & Gynaecology. 2024;131(9):1296-1305. doi:10.1111/1471-0528.17773

BibTeX
@article{Cano2024,
  author = {Cano, Antonio and Nappi, Rossella E and Santoro, Nanette and Stute, Petra and Blogg, Martin and English, Marci L and Morga, Antonia and Scrine, Ludmila and Siddiqui, Emad and Ottery, Faith D},
  title = {Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2024},
  volume = {131},
  number = {9},
  pages = {1296--1305},
  doi = {10.1111/1471-0528.17773}
}
Kostenlos starten →